Sawynok J, Reid A
Department of Pharmacology, Dalhousie University, Halifax, NS, Canada.
Eur J Pharmacol. 1997 Jul 9;330(2-3):115-21. doi: 10.1016/s0014-2999(97)01001-7.
The pronociceptive effects of adenosine 5'-triphosphate (ATP) were examined in the low concentration formalin model (0.5%) by coadministration of ATP, ATP analogs (alpha,beta-methylene-ATP and 2-methylthio-ATP) and antagonists (suramin, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid) with formalin and determining effects on the expression of flinching behaviours. Coadministration of ATP (5-500 nmol) with formalin enhanced phase 2 (12-60 min after injection) but not phase 1 (0-10 min after injection) responses. alpha,beta-methylene-ATP (0.5-50 nmol) but not 2-methylthio-ATP (50-500 nmol) produced a similar enhancement of activity, generating an order of potency of alpha,beta-methylene-ATP, ATP >> 2-methylthio-ATP. This enhancement was primarily expressed in the latter part of phase 2, 30-60 min after injection. Coadministration of suramin 50-500 nmol, a non-selective P2X and P2Y purinoceptor antagonist and pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid 5-500 nmol, a selective P2X purinoceptor antagonist, dose-dependently inhibited the augmentation of the formalin response by ATP 50 nmol, but did not reduce the response to formalin itself. Pretreatment for 30 min with higher doses of suramin inhibited the response to formalin (0.5%, 1.5%) and this appeared to be by a systemically mediated action as it was seen following administration into the contralateral paw. The results of this study provide evidence in support of a P2X purinoceptor mediated augmentation of the pain signal by ATP. The delayed time-course of the effect suggests that it may occur in concert with other mediators that are recruited by the inflammatory process, rather than reflecting a direct depolarization of sensory nerves. Other behavioural paradigms may be required to examine the fast onset, direct effect. Suramin appears to exert both local and systemic effects on the expression of pain behaviours in response to formalin.
通过将三磷酸腺苷(ATP)、ATP类似物(α,β-亚甲基-ATP和2-甲硫基-ATP)以及拮抗剂(苏拉明、磷酸吡哆醛-6-偶氮苯-2',4'-二磺酸)与福尔马林共同给药,并测定对退缩行为表达的影响,在低浓度福尔马林模型(0.5%)中研究了ATP的促伤害感受作用。ATP(5 - 500 nmol)与福尔马林共同给药增强了第2期(注射后12 - 60分钟)的反应,但未增强第1期(注射后0 - 10分钟)的反应。α,β-亚甲基-ATP(0.5 - 50 nmol)而非2-甲硫基-ATP(50 - 500 nmol)产生了类似的活性增强,产生的效力顺序为α,β-亚甲基-ATP、ATP >> 2-甲硫基-ATP。这种增强主要在注射后30 - 60分钟的第2期后半段表现出来。50 - 500 nmol的苏拉明(一种非选择性P2X和P2Y嘌呤受体拮抗剂)和5 - 500 nmol的磷酸吡哆醛-6-偶氮苯-2',4'-二磺酸(一种选择性P2X嘌呤受体拮抗剂)与50 nmol的ATP共同给药,剂量依赖性地抑制了福尔马林反应的增强,但未降低对福尔马林本身的反应。用更高剂量的苏拉明预处理30分钟可抑制对福尔马林(0.5%,1.5%)的反应,这似乎是通过全身介导的作用,因为在对侧爪给药后也能观察到这种现象。本研究结果为ATP通过P2X嘌呤受体介导增强疼痛信号提供了证据。该效应的延迟时间进程表明,它可能与炎症过程中募集的其他介质协同发生,而不是反映感觉神经的直接去极化。可能需要其他行为范式来研究快速起效的直接效应。苏拉明似乎对福尔马林诱导的疼痛行为表达具有局部和全身作用。